GW Pharmaceuticals to let Almirall sell cannabis-derived drug in Mexico
This article was originally published in Scrip
GW Pharmaceuticals has amended its Sativex licence agreement with Almirall. The Spanish firm now has rights to market Sativex in Mexico and GW is entitled to a new near term milestone payment of €12 million (£10 million).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.